Generated by AI
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections. Atea Pharmaceuticals’ current programs center on treatments for hepatitis C, including a late-stage regimen combining bemnifosbuvir and ruzasvir, as well as broader antiviral research across other RNA virus targets. The company also works on therapies for hepatitis E and other viral diseases, reflecting its emphasis on unmet medical needs in infectious disease. Its portfolio is designed around small-molecule oral medicines, which are intended to support convenient outpatient treatment options and address diseases that can require long-term or difficult-to-administer care. Based in Boston, Massachusetts, Atea Pharmaceuticals operates in the biopharmaceutical sector, where antiviral drug development plays a significant role in advancing treatment choices for patients and healthcare providers.
Website225 Franklin Street
Boston, MA, 02110
United States
Summary of Jul 28's posts. Generated by AI.
Summary of Nov 5's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about AVIR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.